Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitoxantrone encapsulated nanocells - EnGeneIC

Next Previous
Drug Profile

Mitoxantrone encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVMitoxantrone; EEDVSMit; EGFR-ErbituxEDVsMIT; Kid EDV; Mitoxantrone packaged EDV™ nanocells - EnGeneIC; Mitoxantrone packaged EnGeneIC Delivery Vehicle; Mitoxantrone packaged EnGeneIC Dream Vector

Latest Information Update: 22 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EnGeneIC
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued CNS cancer; Solid tumours

Most Recent Events

  • 22 Feb 2022 Discontinued - Phase-I for CNS cancer (In adolescents, In children, Recurrent, Second-line therapy or greater) in Australia (IV) (EnGeneIC pipeline, February 2022)
  • 22 Feb 2022 Discontinued - Phase-I for Solid tumours (In adolescents, In children, Recurrent, Second-line therapy or greater) in Australia (IV) (EnGeneIC pipeline, February 2022)
  • 14 Feb 2022 Engeneic terminates the phase I ECREST trial in CNS cancer and Solid tumours (In adolescents, In children, Recurrent, Second-line therapy or greater) in Australia (IV) as mitoxantrone encapsulated nanocells is no longer in production (NCT02687386)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top